Edwards Commander Delivery System (9600LDS20; 9600LDS23; 9600LDS26; 9600LDS29)
Edwards Lifesciences, LLC · Decision date Jun 30, 2026
What did the FDA decide?
FDA records P200015/S078 as a supplement to PMA P200015, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 30, 2026.
FDA approval order statement
implementation of an automated inspection spreadsheet during an incoming inspection
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200015/S078
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPV
- Decision code
- OK30
- Decision date
- Jun 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulmonary valve prosthesis percutaneously delivered.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPV
- FDA device class
- f
For the original device and its historical approval scope, see PMA P200015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200015 · Original PMA
Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System
P200015/S070 · Related supplement
Edwards Commander Delivery System: 9600LDS23, 9600LDS26, 9600LDS29 9750CM23, 9750CM26, 9750CM29
P200015/S071 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve
P200015/S068 · Related supplement
Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System
P200015/S073 · Related supplement
Edwards Commander Delivery System (9600LDS20, 9600LDS23 9600LDS26, 9600LDS29)
P200015/S074 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System
P200015/S075 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve
P200015/S072 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System
P200015/S076 · Related supplement
Edwards SAPIEN 3 Transcatheter Pulmonary Valve (TPV) System with Alterra Adaptive Prestent
P200015/S078 received
Application receipt date recorded by FDA.
P200015/S078 · FDA decision
30-Day Notice
P200015/S079 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve
P200015/S069 · Related supplement
Edwards SAPIEN 3 Pulmonic Delivery System: 9630PL29
P200015/S080 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX20; 9600TFX23; 9600TFX26; 9600TFX29)
P200015/S081 · Related supplement
Edwards SAPIEN 3 Pulmonic Delivery System (9630PL29); Edwards Alterra Adaptive Prestent System (29AP4045)
P200015/S083 · Related supplement
Edwards Crimper (9600LDS20, 9600LDS23, 9600LDS26, 9600LDS29)
P200015/S077 · Related supplement
SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent
P200015/S084 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX)
Timeline entries are records held by MedtechLedger for P200015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200015
Explore the linked device profile
Other records with product code NPV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Harmony TPV SystemP200046/S052 | Medtronic, Inc. | PMA supplement | Sep 30, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Jun 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P200015/S078
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



